Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

View Full Paper
Ask AI
Bookmark
Share

Authors

CJChristopher E. JensenUniversity of North Carolina at Chapel HillNLNicole LamannaNewYork–Presbyterian HospitalPBPaul BarrUniversity of Rochester

Discussion

Loading...

Member takes

Overview

Real-world data reveals effective prophylaxis against tumor lysis syndrome during venetoclax initiation in CLL patients, suggesting simplified monitoring.

Key Points

  • To evaluate venetoclax initiation prophylaxis and monitoring outcomes during treatment in patients with chronic lymphocytic leukemia.
  • Retrospective analysis from 4 US sites of the CLL CORE study
  • Included adult patients with CLL/SLL who started venetoclax and obinutuzumab in first line
  • Monitored tumor burden, prophylaxis measures, and interventions during venetoclax ramp-up
  • 72 patients met inclusion criteria, with 98.6% completing venetoclax ramp-up
  • No cases of tumor lysis syndrome were reported during the ramp-up period
  • Most patients received prophylactic interventions, including hydration and antihyperuricemics

Cite This Study

Jensen et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d86dhttps://doi.org/10.1182/blood-2025-3885
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcome of low-frequency outpatient monitoring for venetoclax initiation in CLL: Single-center experience.2026
  2. 2SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL2026
  3. 3A retrospective observational study of rapid titration of venetoclax (VEN) in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).2024 · 1 citations
  4. 4Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia2025
  5. 5Cytoreduction-Adapted Outpatient Venetoclax Ramp-Up in CLL/SLL: A Real-World Pilot Study2026